Comparative Pharmacology
Head-to-head clinical analysis: SEPHIENCE versus TOVALT ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEPHIENCE versus TOVALT ODT.
SEPHIENCE vs TOVALT ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEPHIENCE (pegfilgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog. It binds to G-CSF receptors on hematopoietic cells, stimulating proliferation, differentiation, and release of neutrophils from bone marrow.
Tovalt ODT (selegiline) is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). At therapeutic doses, it inhibits MAO-B more selectively than MAO-A, leading to increased levels of dopamine in the brain.
Adults: 200 mg orally twice daily with food.
20 mg sublingually as needed for BTP, with a minimum interval of 2 hours between doses; maximum 4 doses per day.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults, allowing for twice-daily dosing. Half-life may be prolonged in renal impairment (up to 30 hours in severe cases).
Terminal elimination half-life approximately 40–60 hours after multiple dosing; clinical context: reaches steady-state after 2–3 weeks.
SEPHIENCE is primarily eliminated via renal excretion (approximately 70% as unchanged drug) and biliary/fecal excretion (approximately 25% as metabolites and unchanged drug).
Primarily hepatic metabolism; 70–80% as inactive metabolites in urine, <5% unchanged in urine, 20–30% fecal.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic